scholarly journals A randomized comparative study of MIP and MMR vaccine for the treatment of cutaneous warts

2021 ◽  
Vol 66 (2) ◽  
pp. 151
Author(s):  
Amandeep Kaur ◽  
BalvinderKaur Brar ◽  
Sumir Kumar ◽  
SukhmaniKaur Brar ◽  
AmarbirSingh Boparai ◽  
...  
Keyword(s):  
Comparative Study ◽  
Mmr Vaccine ◽  
Cutaneous Warts

Immunotherapy in cutaneous warts: comparative clinical Study between MMR vaccine, tuberculin, and BCG Vaccine

2021 ◽  
Author(s):  
Engi Seif E. Shaker ◽  
Noha N. Doghim ◽  
Arwa Mhammad Hassan ◽  
Samia S. Musafa ◽  
Mohamed M. Fawzy
Keyword(s):  
Clinical Study ◽  
Bcg Vaccine ◽  
Mmr Vaccine ◽  
Comparative Clinical Study ◽  
Cutaneous Warts

scholarly journals Efficacy of intralesional MMR vaccine in treatment of single or multiple refractory cutaneous warts

2018 ◽  
Vol 105 (4) ◽  
pp. 498-508
Author(s):  
Mohd Mohtashim ◽  
Syed Suhail Amin ◽  
Mohammad Adil ◽  
Tasleem Arif ◽  
Manu Singh ◽  
...  
Keyword(s):  
Mmr Vaccine ◽  
Cutaneous Warts

scholarly journals Effectiveness of measles, mumps and rubella vaccine as immunotherapeutic agent for cutaneous viral warts

2020 ◽  
Vol 6 (3) ◽  
pp. 439
Author(s):  
Anupama Devi Wahengbam ◽  
Jeyakumari Jeevan ◽  
Sowmya Dogiparthi
Keyword(s):  
Clinical Studies ◽  
Single Agent ◽  
Complete Response ◽  
Mmr Vaccine ◽  
Rubella Vaccine ◽  
Immunotherapeutic Agent ◽  
Management Evaluation ◽  
Cutaneous Wart ◽  
Short Narrative ◽  
Cutaneous Warts

<p>Immunotherapy for management of cutaneous wart with measles, mumps and rubella vaccine (MMR) is a promising new modality of management. Evaluation of the same has been done by various studies over the years reporting its effectiveness. A literature search was done using PubMed and google scholar. This short narrative review documents the response rates in various clinical studies done till 2019 which have reported the efficacy of MMR vaccine as an immunotherapeutic agent which ranged from 26-84% graded as complete response which is complete clearance of the treated warts. These studies were performed for evaluating MMR vaccine as single agent or done in comparison with other therapeutic agents. The broad range of responses points to a need of doing further clinical studies which will substantiate the effectiveness of MMR vaccine in the treatment of cutaneous warts.</p>

scholarly journals Intralesional Measles, Mumps, and Rubella Vaccine for Cutaneous Warts: A Systematic Review and Meta-analysis

2019 ◽  
Vol 53 (2) ◽  
Author(s):  
Patricia A. Nacianceno ◽  
Marie Len A. Camaclang ◽  
Francisca DC. Roa
Keyword(s):  
Risk Ratio ◽  
Meta Analysis ◽  
P Value ◽  
Cell Mediated Immunity ◽  
Mmr Vaccine ◽  
Papilloma Virus ◽  
Online Databases ◽  
Significant Difference ◽  
Cutaneous Warts

Background. Warts, caused by the human papilloma virus (HPV), are mucocutaneous proliferations controlled by cell-mediated immunity. Intralesional immunotherapy with measles, mumps, and rubella (MMR) vaccine, is postulated to induce a higher immune response for clearance of lesions. Objective. To assess the efficacy, safety and effect on recurrence of intralesional MMR vaccine for the treatment of warts. Methods. We searched online databases for randomized controlled trials on intralesional MMR vaccine for warts. Effects measured were the complete clearance of target and distant warts, adverse events noted and recurrence after treatment duration. Results. Four RCTs comparing intralesional MMR vaccine and placebo were assessed. Meta-analysis showed a risk ratio of 0.24 [95% CI: 0.18, 0.34] favoring intralesional MMR vaccine and a highly significant difference in completely clearing target warts (P-value <0.00001) versus placebo. Three of the 4 trials assessed response of distant warts showing a risk ratio of 0.28 [95% CI: 0.08, 0.96] and a significant difference (P=0.04) versus placebo. Pain and flu-like symptoms were the most common side effects with no recurrence seen after 3-6 months. Conclusions. Intralesional MMR vaccine significantly reduces and clears target and distant warts as compared to placebo. It is a generally safe intervention with lasting effect assessed up to 6 months follow-up.

scholarly journals Comparison of cryotherapy versus intralesional measles, mumps, rubella vaccine versus their combination therapy in Indian patients with cutaneous wart: a single centre prospective observational study

2019 ◽  
Vol 5 (4) ◽  
pp. 715
Author(s):  
Mithila Uday Vanarase
Keyword(s):  
Observational Study ◽  
Group Treatment ◽  
Prospective Observational Study ◽  
Intralesional Injection ◽  
Mmr Vaccine ◽  
Indian Patients ◽  
Cutaneous Wart ◽  
Group A ◽  
Group B ◽  
Cutaneous Warts

<p class="abstract"><strong>Background:</strong> Need for more effective and less time consuming therapeutic method is current necessity for treatment of cutaneous warts. The objective of the study was to evaluate and compare the efficacy, safety of cryotherapy versus intralesional measles, mumps, rubella (MMR) vaccine versus combination of cryotherapy and intralesional MMR vaccine in Indian patients with cutaneous wart.</p><p class="abstract"><strong>Methods:</strong> This prospective observational study was conducted in 60 patients of cutaneous warts. Patients were divided into three groups viz., group A, group B and group C. Group A was treated with cryotherapy alone, Group B received intralesional injection 0.1 to 0.3 ml of MMR vaccine alone and Group C received combination of group A and group B therapy. In each group treatment was repeated at 3 week interval for a maximum of 4 sittings. Percentage of improvement was evaluated using visual analogue scale (VAS) for local as well as distant (non-inoculated) warts. Follow-up was made every 2 months till 4 months to detect any recurrence.<strong></strong></p><p class="abstract"><strong>Results:</strong> For local warts in second half of treatment (12<sup>th</sup> week) patients of Group B and Group C showed significantly better response than patients in Group A. For distant warts in first half of treatment session patients showed significantly better response to Group C than as compared to Group B therapy (p&lt;0.039).</p><p class="abstract"><strong>Conclusions:</strong> Immunotherapy with MMR is superior treatment than cryotherapy for cutaneous warts with minimum side effects but the combination of cryotherapy with intralesional MMR has shown to have complementary effect in treatment response.</p>

scholarly journals Intralesional Measles Mumps Rubella vaccine versus BCG in the treatment of multiple cutaneous warts: a comparative study

2021 ◽  
Vol 12 (e) ◽  
pp. e82-e82
Author(s):  
Gopal Nayana ◽  
Nirvanappa Vinay ◽  
H R Umadevi ◽  
M R Suresh ◽  
Nagesha Parvathi
Keyword(s):  
Comparative Study ◽  
Global Assessment ◽  
Therapeutic Response ◽  
Group 14 ◽  
Rubella Vaccine ◽  
Complete Clearance ◽  
Assessment Scores ◽  
Significant Difference ◽  
Cutaneous Warts

Background: Verrucae or warts are benign epithelial proliferations that occur due to accumulation of keratinocytes induced by HPV. Immunotherapy is a new promising modality which uses the principle of activation of one’s own immunity against the disease. Materials and methods: The study included 40 patients with multiple cutaneous warts in two groups of 20 each. Assigned treatment was injected into the single largest wart at an interval of 3 weeks until complete clearance or for a maximum of 3 times. Results: A statistically significant difference (p=0.018) was seen in the therapeutic response when compared to that of the BCG. All 20(100%) patients in the MMR group showed >50% clearance while in the BCG group 14(70%) patients showed >50% clearance according to Physician’s Global Assessment scores. Conclusions: Intralesional immunotherapy with MMR and BCG vaccines are both safe and promising whereas the therapy with MMR stands out with statistically significant results.

Sign in / Sign up

Export Citation Format

Share Document